勒梅特微管醫療 LMAT 深 滬
交易中 06-18 11:18:27 美东时间
93.845
+1.635
+1.77%
華盛通- 最 高94.09
- 今 開92.68
- 成交量 11.80万股
- 最 低 92.68
- 昨 收 92.21
- 總市值 21.44亿
- 52周最高 117.76
- 市盈率 靜 37.27
- 換手率 0.52%
- 52周最低 78.105
- 委 比 -16.67%
- 總股本 2285.07万
- 歷史最高 117.76
- 量 比 1.72
- 振 幅 1.53%
- 歷史最低 -0.305
- 每 手 1
- 風險率 10.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多LeMaitre Vascular shareholders elect Roberts, Roush as directors
LeMaitre Vascular shareholders elect Roberts, Roush as directors LeMaitre Vascular held its annual shareholder meeting on June 2, 2026. Shareholders elected David B. Roberts, John A. Roush as directors. Shareholders ratified Grant Thornton LLP as independent registered public accounting firm for the
06-05 18:02
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
LeMaitre to Present at the Bank of America Healthcare Conference
LeMaitre Vascular, Inc. announced that its management will present at the Bank of America Healthcare Conference on May 13, 2026, at 5:15 PM PT. The company specializes in devices, implants, and services for treating peripheral vascular disease, affecting over 200 million globally. Additional details are available at www.lemaitre.com.
05-07 21:15
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
Wells Fargo Maintains Equal-Weight on LeMaitre Vascular, Raises Price Target to $104
Wells Fargo analyst Nathan Treybeck maintains LeMaitre Vascular (NASDAQ:LMAT) with a Equal-Weight and raises the price target from $94 to $104.
05-06 21:44
LeMaitre Vascular Reports Q1 2026 Results: Full Earnings Call Transcript
On Tuesday, LeMaitre Vascular (NASDAQ:LMAT) discussed first-quarter financial r...
05-06 06:10
LeMaitre Vascular Sees Q2 GAAP EPS $0.79-$0.84 vs $0.75 Est; Sees Sales $70.500M-$72.500M vs $71.105M Est
LeMaitre Vascular (NASDAQ:LMAT) is looking for Q2 GAAP EPS of $0.79-$0.84 vs $0.75 analyst estimate. sees sales of $70.500 million-$72.500 million vs $71.105 million analyst estimate.
05-06 04:08
Earnings Scheduled For May 5, 2026
Companies Reporting Before The Bell • Repligen (NASDAQ:RGEN) is projected to re...
05-05 19:12
LeMaitre Vascular announces annual shareholder meeting
LeMaitre Vascular announces annual shareholder meeting LeMaitre Vascular schedules annual shareholder meeting in Burlington, Massachusetts on June 2, 2026. Shareholders will vote on election of two Class II directors, including David B. Roberts and John A. Roush. Advisory vote set on 2025 named exec
04-14 19:35
LeMaitre Vascular Announces Board Changes and Size Reduction
An update from Lemaitre Vascular ( ($LMAT) ) is now available. On April 8, 2026...
04-14 19:19
